Titre : Carcinome pulmonaire à petites cellules

Carcinome pulmonaire à petites cellules : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Carcinome pulmonaire à petites cellules : Questions médicales les plus fréquentes", "headline": "Carcinome pulmonaire à petites cellules : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Carcinome pulmonaire à petites cellules : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-01", "dateModified": "2026-04-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Carcinome pulmonaire à petites cellules" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Carcinome bronchogénique", "url": "https://questionsmedicales.fr/mesh/D002283", "about": { "@type": "MedicalCondition", "name": "Carcinome bronchogénique", "code": { "@type": "MedicalCode", "code": "D002283", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C08.785.520.100.220" } } }, "about": { "@type": "MedicalCondition", "name": "Carcinome pulmonaire à petites cellules", "alternateName": "Small Cell Lung Carcinoma", "code": { "@type": "MedicalCode", "code": "D055752", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Lynette M Sholl", "url": "https://questionsmedicales.fr/author/Lynette%20M%20Sholl", "affiliation": { "@type": "Organization", "name": "Department of Pathology, Harvard Medical School, Boston, Massachusetts." } }, { "@type": "Person", "name": "Minglei Zhuo", "url": "https://questionsmedicales.fr/author/Minglei%20Zhuo", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China." } }, { "@type": "Person", "name": "Mirentxu Santos", "url": "https://questionsmedicales.fr/author/Mirentxu%20Santos", "affiliation": { "@type": "Organization", "name": "Basic Research Department, Molecular Oncology Unit, Madrid, Spain." } }, { "@type": "Person", "name": "Hao Chen", "url": "https://questionsmedicales.fr/author/Hao%20Chen", "affiliation": { "@type": "Organization", "name": "Department of Pathology, Shihezi University School of Medicine & the First Affiliated Hospital to Shihezi University School of Medicine, Shihezi, Xinjiang, China." } }, { "@type": "Person", "name": "Ye Wang", "url": "https://questionsmedicales.fr/author/Ye%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Molecular subtype expression and genomic profiling differ between surgically resected pure and combined small cell lung carcinoma.", "datePublished": "2023-08-14", "url": "https://questionsmedicales.fr/article/37586462", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.humpath.2023.08.003" } }, { "@type": "ScholarlyArticle", "name": "Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.", "datePublished": "2023-05-01", "url": "https://questionsmedicales.fr/article/37175833", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms24098129" } }, { "@type": "ScholarlyArticle", "name": "Novel Therapeutic Options for Small Cell Lung Cancer.", "datePublished": "2023-10-23", "url": "https://questionsmedicales.fr/article/37870696", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11912-023-01465-7" } }, { "@type": "ScholarlyArticle", "name": "Potential predictors of immunotherapy in small cell lung cancer.", "datePublished": "2023-05-03", "url": "https://questionsmedicales.fr/article/37206058", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/pore.2023.1611086" } }, { "@type": "ScholarlyArticle", "name": "CDK6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma.", "datePublished": "2023-11-10", "url": "https://questionsmedicales.fr/article/37950078", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10142-023-01253-3" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies de l'appareil respiratoire", "item": "https://questionsmedicales.fr/mesh/D012140" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs de l'appareil respiratoire", "item": "https://questionsmedicales.fr/mesh/D012142" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs du poumon", "item": "https://questionsmedicales.fr/mesh/D008175" }, { "@type": "ListItem", "position": 5, "name": "Tumeurs des bronches", "item": "https://questionsmedicales.fr/mesh/D001984" }, { "@type": "ListItem", "position": 6, "name": "Carcinome bronchogénique", "item": "https://questionsmedicales.fr/mesh/D002283" }, { "@type": "ListItem", "position": 7, "name": "Carcinome pulmonaire à petites cellules", "item": "https://questionsmedicales.fr/mesh/D055752" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Carcinome pulmonaire à petites cellules - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Carcinome pulmonaire à petites cellules", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-04-28", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Carcinome pulmonaire à petites cellules", "description": "Comment diagnostique-t-on le carcinome pulmonaire à petites cellules ?\nQuels tests sont utilisés pour évaluer l'étendue du cancer ?\nQuels marqueurs tumoraux sont associés à ce cancer ?\nLe diagnostic précoce est-il possible ?\nQuelle est l'importance de la biopsie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D055752?page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Carcinome pulmonaire à petites cellules", "description": "Quels sont les symptômes courants du carcinome pulmonaire à petites cellules ?\nLa fatigue est-elle un symptôme fréquent ?\nPeut-on avoir des symptômes neurologiques ?\nLes symptômes varient-ils selon le stade du cancer ?\nY a-t-il des signes d'alerte à surveiller ?", "url": "https://questionsmedicales.fr/mesh/D055752?page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Carcinome pulmonaire à petites cellules", "description": "Comment peut-on prévenir le carcinome pulmonaire à petites cellules ?\nLe dépistage précoce est-il recommandé ?\nY a-t-il des vaccins contre ce type de cancer ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes antécédents familiaux influencent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D055752?page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Carcinome pulmonaire à petites cellules", "description": "Quels traitements sont disponibles pour ce type de cancer ?\nLa chirurgie est-elle une option pour tous les patients ?\nComment la chimiothérapie est-elle administrée ?\nQuels sont les effets secondaires des traitements ?\nLa radiothérapie est-elle utilisée en complément ?", "url": "https://questionsmedicales.fr/mesh/D055752?page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Carcinome pulmonaire à petites cellules", "description": "Quelles sont les complications possibles du carcinome pulmonaire à petites cellules ?\nComment les métastases affectent-elles le traitement ?\nL'insuffisance respiratoire est-elle fréquente ?\nLes infections sont-elles un risque pour les patients ?\nQuelles sont les complications liées aux traitements ?", "url": "https://questionsmedicales.fr/mesh/D055752?page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Carcinome pulmonaire à petites cellules", "description": "Quels sont les principaux facteurs de risque du carcinome pulmonaire à petites cellules ?\nL'âge influence-t-il le risque de développer ce cancer ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'exposition professionnelle peut-elle être un facteur de risque ?\nLe sexe influence-t-il le risque de ce cancer ?", "url": "https://questionsmedicales.fr/mesh/D055752?page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on le carcinome pulmonaire à petites cellules ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par imagerie (CT, IRM) et biopsie des tissus pulmonaires." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'étendue du cancer ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie comme la TEP et des examens sanguins sont utilisés." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont associés à ce cancer ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs comme le CEA et le NSE peuvent être élevés dans ce type de cancer." } }, { "@type": "Question", "name": "Le diagnostic précoce est-il possible ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic précoce est rare, car les symptômes apparaissent souvent tardivement." } }, { "@type": "Question", "name": "Quelle est l'importance de la biopsie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie permet de confirmer la présence de cellules cancéreuses et leur type." } }, { "@type": "Question", "name": "Quels sont les symptômes courants du carcinome pulmonaire à petites cellules ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent toux persistante, essoufflement, douleur thoracique et perte de poids." } }, { "@type": "Question", "name": "La fatigue est-elle un symptôme fréquent ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fatigue est courante et peut être due à l'anémie ou à la maladie avancée." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes neurologiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes neurologiques peuvent survenir si le cancer se propage au cerveau." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le stade du cancer ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent s'aggraver avec l'avancement du stade de la maladie." } }, { "@type": "Question", "name": "Y a-t-il des signes d'alerte à surveiller ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme une toux persistante ou des crachats sanguins doivent être évalués." } }, { "@type": "Question", "name": "Comment peut-on prévenir le carcinome pulmonaire à petites cellules ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe principalement par l'arrêt du tabac et l'évitement de l'exposition aux polluants." } }, { "@type": "Question", "name": "Le dépistage précoce est-il recommandé ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage par scanner est recommandé pour les fumeurs à haut risque." } }, { "@type": "Question", "name": "Y a-t-il des vaccins contre ce type de cancer ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir ce cancer." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en fruits et légumes peut réduire le risque de cancer du poumon." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de développer ce cancer." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour ce type de cancer ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chimiothérapie, la radiothérapie et parfois la chirurgie." } }, { "@type": "Question", "name": "La chirurgie est-elle une option pour tous les patients ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, la chirurgie est généralement réservée aux cas localisés et non métastatiques." } }, { "@type": "Question", "name": "Comment la chimiothérapie est-elle administrée ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie peut être administrée par voie intraveineuse ou orale, selon le protocole." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée en complément ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut être utilisée pour réduire les tumeurs ou soulager les symptômes." } }, { "@type": "Question", "name": "Quelles sont les complications possibles du carcinome pulmonaire à petites cellules ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la métastase, l'insuffisance respiratoire et les infections." } }, { "@type": "Question", "name": "Comment les métastases affectent-elles le traitement ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases compliquent le traitement et peuvent nécessiter des approches plus agressives." } }, { "@type": "Question", "name": "L'insuffisance respiratoire est-elle fréquente ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'insuffisance respiratoire est une complication courante dans les stades avancés." } }, { "@type": "Question", "name": "Les infections sont-elles un risque pour les patients ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent être plus susceptibles aux infections en raison de l'immunosuppression." } }, { "@type": "Question", "name": "Quelles sont les complications liées aux traitements ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent entraîner des complications comme des pneumonies ou des effets secondaires graves." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque du carcinome pulmonaire à petites cellules ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme est le principal facteur de risque, suivi de l'exposition à l'amiante et à la pollution." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de développer ce cancer ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout chez les personnes de plus de 60 ans." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies pulmonaires augmentent le risque de cancer du poumon." } }, { "@type": "Question", "name": "L'exposition professionnelle peut-elle être un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des substances cancérigènes au travail augmente le risque." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque de ce cancer ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les hommes ont un risque plus élevé que les femmes, bien que l'écart se réduise." } } ] } ] }

Sources (10000 au total)

Novel Therapeutic Options for Small Cell Lung Cancer.

The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pa... In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Rec...

CDK6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma.

The roles of cyclin-dependent kinase 6 (CDK6) in various cancers, including small cell lung carcinoma (SCLC), remain unclear. Here, 111,54 multi-center samples were investigated to determine the expre...

Exosomes secreted by metastatic cancer cells promotes epithelial mesenchymal transition in small cell lung carcinoma: The key role of Src/TGF-β1 axis.

Exosome-mediated epithelial mesenchymal transition (EMT) is key to cancer metastasis. c-Src is involved in the secretion of exosomes and initiation of EMT. Effects of exosomes from metastatic non-smal...

Surgery for stage IIB-IIIB small cell lung cancer.

The NCCN guidelines do not recommend surgery for T3-4N0M0/T1-4N1-2M0 small cell lung cancer (SCLC) due to a lack of evidence.... Data of patients with T3-4N0M0/T1-4N1-2M0 SCLC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database to determine the impact of surgery on this population. The Kaplan-Mei... In total, 8572 patients with SCLC treated without surgery and 342 patients treated with surgery were included in this study. The PSM-adjusted hazard ratio (HR, 95% CI) for surgery vs. no surgery, subl... Lobectomy improved OS in patients with T3-4N0M0/T1-4N1-2M0 SCLC, while pneumonectomy also demonstrated a tendency to improve OS without statistical significance; however, sublobectomy showed no surviv...

A Genome-Wide Association Study of Small Cell Lung Cancer.

Small cell lung cancer (SCLC) comprises 10-15% of all lung cancer cases and is the most aggressive histological type. Survival is poor and the molecular landscape of this disease is extraordinarily co... Incident cases were consecutively recruited from 8 hospitals from different regions of Spain. Controls were recruited from the same hospitals using a frequency sampling based on age and sex distributi... We included 271 SCLC cases and 557 controls. We found evidence (p-values<10... This study provides biological evidence for pathways related to SCLC, offering novel loci for further research....

Pathologic collision of urinary bladder urothelial carcinoma with small cell carcinoma: a case report.

Urothelial carcinoma is a major subtype of bladder cancer and small cell carcinoma (SCC) is a rare type of cancer in clinical practice. Pathologic collision of urinary bladder urothelial carcinoma wit... Here, we report a patient with high-grade papillary carcinoma which changed to collision tumor with SCC. The patient underwent radical cystectomy; however, neck and mediastinum lymph nodes metastases ... We hypothesized the mechanism underlying this pathological transformation. For patients with urothelial bladder cancer, pathological analysis should be conducted to allow standardized and persistent t... We recommend that radical cystectomy be performed early enough for patients with non-muscle invasive bladder cancer, who are at a high risk of tumor recurrence. However, this conclusion needs to be va...